Novo Nordisk’s shock decision to oust its chief executive has resulted in the Ozempic maker once again becoming Europe’s ...

It’s the hot-shot fix that took Hollywood — and now high school — by storm. Ozempic and other so-called “miracle” weight-loss ...

Positive news from the laboratory was the wind beneath the wings of Novo Nordisk (NYSE: NVO) stock on Thursday. The ...

Some hairstylists have confirmed an uptick in clients who complain about losing hair while on weight-loss journeys.

Activist hedge fund Parvus Asset Management is building a stake in Ozempic-maker Novo Nordisk as the drugmaker hunts for a ...

Experts discuss how weight loss can trigger temporary hair loss, with hairstylists and an endocrinologist providing insights ...

Novo Nordisk’s drugs are being linked to an eye condition that can cause vision loss, while health tech companies made CNBC’s ...

Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market. Read why I ...

Novo Nordisk is making moves to retain its market share in the weight loss space after Eli Lilly's tirzepatide won a ...

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

Women employed at Novo Nordisk A/S are now paid more on average than the men working at the maker of blockbuster drugs Wegovy ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...